Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | SDCBP | O00560 | 3/20 | 0.43 |
| ▸ | SDC2 | P34741 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.41 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490744 | 1.00 | NPSR1 (0.46) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5382170 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CA2CA1MAPK1 | |
| SCHEMBL2581847 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CA2CA1MAPK1 | |
| SCHEMBL25663370 | 0.82 | CNR2 (0.36) | NPSR1 | |
| SCHEMBL4937559 | 0.81 | ALDH1A1 (0.44) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL4937544 | 0.81 | ALDH1A1 (0.44) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL30455965 | 0.81 | MMP1 (0.39) | — | |
| Hydrochloric Acid SCHEMBL4936603 | 0.79 | ALDH1A1 (0.43) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4936590 | 0.79 | ALDH1A1 (0.43) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL23408869 | 0.79 | ALDH1A1 (0.49) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232817-B2 | α- and β-amino acid hydroxyethlamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20060094789-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-05-04 | — | — | US | disclosed |
| US-7030161-B2 | α-and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-04-18 | — | — | US | disclosed |
| US-6683648-B2 | ENZYME INHIBITORS SUCH AS 2S-(((DIMETHYLAMINO)ACETYL)AMINO)-N-(3-((((2-HYDROXY-1,1 -DIMETHYLETHYL)AMINO)SULFONYL)(3-METHYL BUTYL)AMINO)-2R-HYDROXY-1S-(PHENYLMETHYL)-PROPYL)-3,3-DIMETHYL BUTANAMIDE, USED FOR PROHYLAXIS OF VIRAL DISEASES | G. D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-6403585-B1 | INHIBITING RETROVIRAL PROTEASES SUCH AS HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE | G. D. SEARLE & CO. | 2002-06-11 | — | — | US | disclosed |
| US-6211176-B1 | AIDS TREATMENT | G. D. SEARLE & CO. | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094789-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors | DNPEP, PEPD, PREP | NPSR1 3664/4885SDCBP 3438/4885SDC2 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.